FEasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld deviCES: Results of a pilot study

Peter K. Kaiser, Yi Zhong Wang, Yu Guang He, Annemarie Weisberger, Stephane Wolf, Craig H. Smith

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

PURPOSE:: This pilot study evaluated the feasibility of the Health Management Tool (HMT), a novel computing system using mobile handheld devices, to remotely monitor retinal visual function daily in patients with neovascular age-related macular degeneration treated with ranibizumab. METHODS:: Patients with neovascular age-related macular degeneration in at least 1 eye (newly diagnosed or successfully treated < 1 year) and eligible for ranibizumab therapy were enrolled in this 16-week, prospective, open-label, single-arm study. Patients performed a shape discrimination hyperacuity test (myVisionTrack [mVT]) daily on the HMT device (iPhone 3GS) remotely and at all clinic visits. Data entered into HMT devices were collected in the HMT database, which also sent reminders for patients to take mVT. RESULTS:: Among 160 patients from 24 U.S. centers enrolled in the study (103 [64%] ≥75 years of age), 84.7% on average complied with daily mVT testing and ∼98.9% complied with at least weekly mVT testing. The HMT database successfully uploaded more than 17,000 mVT assessment values and sent more than 9,000 reminders. CONCLUSION:: Elderly patients with neovascular age-related macular degeneration were willing and able to comply with daily self-testing of retinal visual function using mobile handheld devices in this novel system of remote vision monitoring.

Original languageEnglish (US)
Pages (from-to)1863-1870
Number of pages8
JournalRetina
Volume33
Issue number9
DOIs
StatePublished - Oct 2013

Fingerprint

Macular Degeneration
Equipment and Supplies
Health
Databases
Ambulatory Care

Keywords

  • age-related macular degeneration
  • bestcorrected visual acuity
  • central retinal subfield thickness
  • choroidal neovascularization
  • Health Management Tool
  • myVisionTrack
  • ranibizumab
  • remotemonitoring
  • retinal disease
  • shape discriminationhyperacuity

ASJC Scopus subject areas

  • Ophthalmology

Cite this

FEasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld deviCES : Results of a pilot study. / Kaiser, Peter K.; Wang, Yi Zhong; He, Yu Guang; Weisberger, Annemarie; Wolf, Stephane; Smith, Craig H.

In: Retina, Vol. 33, No. 9, 10.2013, p. 1863-1870.

Research output: Contribution to journalArticle

Kaiser, Peter K. ; Wang, Yi Zhong ; He, Yu Guang ; Weisberger, Annemarie ; Wolf, Stephane ; Smith, Craig H. / FEasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld deviCES : Results of a pilot study. In: Retina. 2013 ; Vol. 33, No. 9. pp. 1863-1870.
@article{cfebca01e0514e14a75faff4edfe145f,
title = "FEasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld deviCES: Results of a pilot study",
abstract = "PURPOSE:: This pilot study evaluated the feasibility of the Health Management Tool (HMT), a novel computing system using mobile handheld devices, to remotely monitor retinal visual function daily in patients with neovascular age-related macular degeneration treated with ranibizumab. METHODS:: Patients with neovascular age-related macular degeneration in at least 1 eye (newly diagnosed or successfully treated < 1 year) and eligible for ranibizumab therapy were enrolled in this 16-week, prospective, open-label, single-arm study. Patients performed a shape discrimination hyperacuity test (myVisionTrack [mVT]) daily on the HMT device (iPhone 3GS) remotely and at all clinic visits. Data entered into HMT devices were collected in the HMT database, which also sent reminders for patients to take mVT. RESULTS:: Among 160 patients from 24 U.S. centers enrolled in the study (103 [64{\%}] ≥75 years of age), 84.7{\%} on average complied with daily mVT testing and ∼98.9{\%} complied with at least weekly mVT testing. The HMT database successfully uploaded more than 17,000 mVT assessment values and sent more than 9,000 reminders. CONCLUSION:: Elderly patients with neovascular age-related macular degeneration were willing and able to comply with daily self-testing of retinal visual function using mobile handheld devices in this novel system of remote vision monitoring.",
keywords = "age-related macular degeneration, bestcorrected visual acuity, central retinal subfield thickness, choroidal neovascularization, Health Management Tool, myVisionTrack, ranibizumab, remotemonitoring, retinal disease, shape discriminationhyperacuity",
author = "Kaiser, {Peter K.} and Wang, {Yi Zhong} and He, {Yu Guang} and Annemarie Weisberger and Stephane Wolf and Smith, {Craig H.}",
year = "2013",
month = "10",
doi = "10.1097/IAE.0b013e3182899258",
language = "English (US)",
volume = "33",
pages = "1863--1870",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - FEasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld deviCES

T2 - Results of a pilot study

AU - Kaiser, Peter K.

AU - Wang, Yi Zhong

AU - He, Yu Guang

AU - Weisberger, Annemarie

AU - Wolf, Stephane

AU - Smith, Craig H.

PY - 2013/10

Y1 - 2013/10

N2 - PURPOSE:: This pilot study evaluated the feasibility of the Health Management Tool (HMT), a novel computing system using mobile handheld devices, to remotely monitor retinal visual function daily in patients with neovascular age-related macular degeneration treated with ranibizumab. METHODS:: Patients with neovascular age-related macular degeneration in at least 1 eye (newly diagnosed or successfully treated < 1 year) and eligible for ranibizumab therapy were enrolled in this 16-week, prospective, open-label, single-arm study. Patients performed a shape discrimination hyperacuity test (myVisionTrack [mVT]) daily on the HMT device (iPhone 3GS) remotely and at all clinic visits. Data entered into HMT devices were collected in the HMT database, which also sent reminders for patients to take mVT. RESULTS:: Among 160 patients from 24 U.S. centers enrolled in the study (103 [64%] ≥75 years of age), 84.7% on average complied with daily mVT testing and ∼98.9% complied with at least weekly mVT testing. The HMT database successfully uploaded more than 17,000 mVT assessment values and sent more than 9,000 reminders. CONCLUSION:: Elderly patients with neovascular age-related macular degeneration were willing and able to comply with daily self-testing of retinal visual function using mobile handheld devices in this novel system of remote vision monitoring.

AB - PURPOSE:: This pilot study evaluated the feasibility of the Health Management Tool (HMT), a novel computing system using mobile handheld devices, to remotely monitor retinal visual function daily in patients with neovascular age-related macular degeneration treated with ranibizumab. METHODS:: Patients with neovascular age-related macular degeneration in at least 1 eye (newly diagnosed or successfully treated < 1 year) and eligible for ranibizumab therapy were enrolled in this 16-week, prospective, open-label, single-arm study. Patients performed a shape discrimination hyperacuity test (myVisionTrack [mVT]) daily on the HMT device (iPhone 3GS) remotely and at all clinic visits. Data entered into HMT devices were collected in the HMT database, which also sent reminders for patients to take mVT. RESULTS:: Among 160 patients from 24 U.S. centers enrolled in the study (103 [64%] ≥75 years of age), 84.7% on average complied with daily mVT testing and ∼98.9% complied with at least weekly mVT testing. The HMT database successfully uploaded more than 17,000 mVT assessment values and sent more than 9,000 reminders. CONCLUSION:: Elderly patients with neovascular age-related macular degeneration were willing and able to comply with daily self-testing of retinal visual function using mobile handheld devices in this novel system of remote vision monitoring.

KW - age-related macular degeneration

KW - bestcorrected visual acuity

KW - central retinal subfield thickness

KW - choroidal neovascularization

KW - Health Management Tool

KW - myVisionTrack

KW - ranibizumab

KW - remotemonitoring

KW - retinal disease

KW - shape discriminationhyperacuity

UR - http://www.scopus.com/inward/record.url?scp=84885022095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885022095&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3182899258

DO - 10.1097/IAE.0b013e3182899258

M3 - Article

C2 - 23609122

AN - SCOPUS:84885022095

VL - 33

SP - 1863

EP - 1870

JO - Retina

JF - Retina

SN - 0275-004X

IS - 9

ER -